AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16423519 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (PM235) - pooled high and low doses
Number of subjects: 150
Study 16423519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 14625664 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐EDDA/HYNIC‐TOC scintigraphy
Number of subjects: 54
Study 14625664 — intervention group
Group type: COMPARATOR
Intervention: (18)F‐FDG PET
Number of subjects: 54
Study 11727665 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN patches (0.4‐0.8 mg/h)
Number of subjects: 50
Study 11727665 — intervention group
Group type: COMPARATOR
Intervention: fenoterol per infusionem (60‐120 micrograms/h)
Number of subjects: 50
Study 9228496 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol (0.050 mg/day)
Number of subjects: 51
Study 9228496 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral conjugated estrogens (0.625 mg/day)
Number of subjects: 51
Study 9228496 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 51
Study 8425628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 41
Study 8425628 — intervention group
Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 41
Study 8425628 — intervention group
Group type: COMPARATOR
Intervention: Intratubal and intrauterine insemination (ITI/IUI)
Number of subjects: 41
Study 3592731 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone dummies
Number of subjects: 0
Study 3592731 — intervention group
Group type: COMPARATOR
Intervention: Latex dummies
Number of subjects: 0
Study 3592731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dummy carriage
Number of subjects: 0
Study 30658096 — intervention group
Group type: EXPERIMENTAL
Intervention: rIPC treatment (n=8)
Number of subjects: 16
Study 30658096 — intervention group
Group type: COMPARATOR
Intervention: Control (n=8)
Number of subjects: 16
Study 28738397 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education with telephone follow-up
Number of subjects: 64
Study 28738397 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 64
Study 26386764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg/day)
Number of subjects: 302
Study 23988179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus cognitive-coping therapy (PCCT)
Number of subjects: 145
Study 23988179 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 145
Study 20607405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole high dose (1.2 mg/kg)
Number of subjects: 45
Study 20607405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole low dose (0.6 mg/kg)
Number of subjects: 45
Study 19409119 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-suture technique (2 Vicryl 2-0 stitches at 3- and 9-o'clock positions)
Number of subjects: 100
Study 19409119 — intervention group
Group type: COMPARATOR
Intervention: 6-suture technique (6 Vicryl 2-0 stitches at 2-, 4-, 6-, 8-, 10-, and 12-o'clock positions)
Number of subjects: 100
Study 19409119 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-suture technique
Number of subjects: 100
Study 19409119 — intervention group
Group type: COMPARATOR
Intervention: 6-suture technique
Number of subjects: 100
Study 17256445 — intervention group
Group type: EXPERIMENTAL
Intervention: locally infused trapidil (5 ‐ 400 microg/min)
Number of subjects: 10
Study 17256445 — intervention group
Group type: COMPARATOR
Intervention: norepinephrine (11 ‐ 1,000 ng/min)
Number of subjects: 10
Study 17256445 — intervention group
Group type: COMPARATOR
Intervention: dinoprost (90 ‐ 5,600 ng/min)
Number of subjects: 10
Study 15097237 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated response
Number of subjects: 195
Study 15097237 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate response
Number of subjects: 195
Study 11125233 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride-impregnated central venous catheter (CVC) (n = 25)
Number of subjects: 70
Study 11125233 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-lumen central venous catheter (CVC) (n = 25)
Number of subjects: 70
Study 9728897 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (2 gm/day over 1 week)
Number of subjects: 12
Study 7828491 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐I+(VT)
Number of subjects: 26
Study 7828491 — intervention group
Group type: COMPARATOR
Intervention: Roux(B‐II)+VT
Number of subjects: 26
Study 3125025 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 400 micrograms bid
Number of subjects: 16
Study 3125025 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg and misoprostol 400 micrograms bid
Number of subjects: 16
Study 3125025 — intervention group
Group type: COMPARATOR
Intervention: untreated patients
Number of subjects: 16
Study 31183593 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based paraprofessional training program
Number of subjects: 40
Study 31183593 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) group
Number of subjects: 40
Study 29494423 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided pharmacogenetics guided (PHG) warfarin dosing
Number of subjects: 205
Study 29494423 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided non pharmacogenetics guided (NPHG) warfarin dosing
Number of subjects: 205
Study 27016718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser at 11.2 mJ per laser channel with 1% density, MAL 160 mg/g, 180 min incubation
Number of subjects: 11
Study 27016718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser at densities of 1%, 2%, 5%, 10%, and 15%
Number of subjects: 11
Study 27016718 — intervention group
Group type: COMPARATOR
Intervention: Ablative fractional Er:YAG laser at 5% density and median incubation time of 80 min MAL
Number of subjects: 11
Study 27016718 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL 80 and 160 mg/g
Number of subjects: 11
Study 24484545 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff supervision
Number of subjects: 393
Study 24484545 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipment
Number of subjects: 393
Study 24484545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 393
Study 24484545 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff + Equipment
Number of subjects: 393
Study 23852294 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (PHF)
Number of subjects: 63
Study 23852294 — intervention group
Group type: COMPARATOR
Intervention: Highly active antiretroviral treatment (HAART)
Number of subjects: 63
Study 23852294 — intervention group
Group type: EXPERIMENTAL
Intervention: PHF-to-HAART arm
Number of subjects: 63
Study 23852294 — intervention group
Group type: EXPERIMENTAL
Intervention: PHF arm at 1 month
Number of subjects: 63
Study 20186439 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1 mg kg(‐1)
Number of subjects: 30
Study 20186439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg kg(‐1) with remifentanil 1 microg kg(‐1) min(‐1)
Number of subjects: 30
Study 20186439 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1 mg kg(‐1)
Number of subjects: 30
Study 20186439 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2‐2.5 mg kg(‐1)
Number of subjects: 30
Study 18243569 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei DN‐114 001 at 10(8) CFU/g
Number of subjects: 85
Study 18243569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 15891924 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.6 mg/kg)
Number of subjects: 53
Study 15891924 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (25 mg/kg)
Number of subjects: 53
Study 15891924 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 53
Study 12965939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF)
Number of subjects: 552
Study 12965939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 10807891 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable stiffness colonoscope (VS)
Number of subjects: 100
Study 10807891 — intervention group
Group type: COMPARATOR
Intervention: Conventional Olympus CF200HL (200HL)
Number of subjects: 100
Study 9273207 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 0
Study 9273207 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+CD8+ lymphocytes
Number of subjects: 0
Study 9273207 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 1518258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk (LR) protocol with leukocytopenic episodes
Number of subjects: 213
Study 1518258 — intervention group
Group type: COMPARATOR
Intervention: Low-risk (LR) protocol without leukocytopenic episodes
Number of subjects: 213
Study 1518258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean relative dose greater than 0.9
Number of subjects: 213
Study 6542606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 0
Study 6542606 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 0
Study 30176897 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose primaquine (0.5 mg base/kg body weight) for 14 days
Number of subjects: 50
Study 30176897 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose primaquine (0.25 mg/kg) for 14 days
Number of subjects: 50
Study 27629871 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 g daily
Number of subjects: 168
Study 27629871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 24851986 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision aid (DA)
Number of subjects: 0
Study 22971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 40
Study 22971528 — intervention group
Group type: COMPARATOR
Intervention: Heating pad application
Number of subjects: 40
Study 19844770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (PR) in Group A (Outerbridge Grades I, II, III)
Number of subjects: 500
Study 19844770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (PR) in Group B (Outerbridge Grade IV)
Number of subjects: 500
Study 19844770 — intervention group
Group type: COMPARATOR
Intervention: Comparison of risk between Group A and Group B
Number of subjects: 500
Study 18580611 — intervention group
Group type: EXPERIMENTAL
Intervention: Four injections of ALVAC-HIV vaccine (vCP1452) at weeks 0, 4, 8, 20
Number of subjects: 65
Study 18580611 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of ALVAC-HIV vaccine (vCP1452) at weeks 4, 8, 20
Number of subjects: 65
Study 18580611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 18580611 — intervention group
Group type: EXPERIMENTAL
Intervention: Four injections of ALVAC-HIV vaccine (vCP1452)
Number of subjects: 65
Study 18580611 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of ALVAC-HIV vaccine (vCP1452)
Number of subjects: 65
Study 18580611 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization (both three and four injections)
Number of subjects: 65
Study 18580611 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 nadir
Number of subjects: 65
Study 15709997 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 999
Study 15709997 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 999
Study 12660570 — intervention group
Group type: EXPERIMENTAL
Intervention: YOn (eyes open in the dark)
Number of subjects: 15
Study 12660570 — intervention group
Group type: COMPARATOR
Intervention: YF (normal eyelid closure)
Number of subjects: 15
Study 12660570 — intervention group
Group type: EXPERIMENTAL
Intervention: YFF (forcibly closed eyelids)
Number of subjects: 15
Study 10778521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg + nimesulide 100 mg
Number of subjects: 10
Study 10778521 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 10
Study 9345406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Betaseron
Number of subjects: 0
Study 9345406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Betaseron
Number of subjects: 0
Study 9345406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1828683 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg x 3 daily)
Number of subjects: 10
Study 1828683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7055434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative peritoneal irrigation (group 2)
Number of subjects: 44
Study 7055434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intraoperative and postoperative peritoneal irrigation (group 3)
Number of subjects: 44
Study 7055434 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal irrigation (group 1)
Number of subjects: 44
Study 7055434 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of all groups
Number of subjects: 44
Study 31776820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative iodine (5 mL of 0.25% povidone-iodine applied at 2 stages)
Number of subjects: 102
Study 31776820 — intervention group
Group type: COMPARATOR
Intervention: Preoperative topical antibiotics (administered 3 days before surgery)
Number of subjects: 102
Study 31898677 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (30 gm daily)
Number of subjects: 104
Study 31898677 — intervention group
Group type: COMPARATOR
Intervention: Digestible starch (control)
Number of subjects: 104
Study 31898677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 30335422 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy for PTSD
Number of subjects: 260
Study 30335422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral therapies for OCD
Number of subjects: 260
Study 30335422 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy in a naturalistic setting
Number of subjects: 260
Study 26888988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower 10-second heart rate variability (HRV)
Number of subjects: 3583
Study 26888988 — intervention group
Group type: COMPARATOR
Intervention: Higher 10-second heart rate variability (HRV)
Number of subjects: 3583
Study 25825091 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) mouth rinse used twice daily for one week
Number of subjects: 18
Study 25825091 — intervention group
Group type: COMPARATOR
Intervention: Mouth rinse without CHX (control group)
Number of subjects: 18
Study 21593784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 21593784 — intervention group
Group type: COMPARATOR
Intervention: Control (no pravastatin)
Number of subjects: 0
Study 18820280 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 143
Study 18820280 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 143
Study 17937843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg first dose, followed by two doses of 5 mg/kg each at 24 hr intervals)
Number of subjects: 36
Study 17937843 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (0.2 mg/kg at 24 hr intervals)
Number of subjects: 36
Study 17937843 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin
Number of subjects: 36
Study 17937843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 36
Study 17937843 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 36
Study 15200437 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of iron (III) sucrose
Number of subjects: 6
Study 15200437 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of iron (III) sucrose
Number of subjects: 6
Study 17355727 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of female rape
Number of subjects: 0
Study 17355727 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of male rape
Number of subjects: 0
Study 10619802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensivists with consensus training
Number of subjects: 99
Study 10619802 — intervention group
Group type: COMPARATOR
Intervention: Intensivists without consensus training
Number of subjects: 99
Study 8796137 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fenfluramine
Number of subjects: 6
Study 8796137 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fenfluramine
Number of subjects: 6
Study 8796137 — intervention group
Group type: COMPARATOR
Intervention: CRH injection
Number of subjects: 6
Study 1620826 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human-tissue-type plasminogen activator (rTPA)
Number of subjects: 62
Study 1620826 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA plus heparin
Number of subjects: 62
Study 1620826 — intervention group
Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 62
Study 1620826 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA with or without heparin
Number of subjects: 62
Study 6538427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg) with phenazone (15 mg/kg)
Number of subjects: 9
Study 6538427 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg) with phenazone (15 mg/kg)
Number of subjects: 9
Study 6538427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and metronidazole
Number of subjects: 9
Study 6538427 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 9
Study 30853816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended venous thromboembolism prophylaxis (vte) with low molecular weight heparin (lmwh)
Number of subjects: 105
Study 30853816 — intervention group
Group type: COMPARATOR
Intervention: No extended venous thromboembolism prophylaxis
Number of subjects: 105
Study 29435853 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR (pathological complete response)
Number of subjects: 383
Study 29435853 — intervention group
Group type: COMPARATOR
Intervention: non-pCR
Number of subjects: 383
Study 29435853 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 383
Study 27322798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone, 45 mg/d
Number of subjects: 101
Study 27322798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 24799157 — intervention group
Group type: COMPARATOR
Intervention: MOBID-2 pain scale
Number of subjects: 352
Study 22137494 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol (2 mg/day for 8 weeks)
Number of subjects: 12
Study 21056439 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention consisting of home-based physical activities, health advice, and aspects of healthcare management over 15 months followed by a 3-month latent period.
Number of subjects: 839
Study 21056439 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (compliant group)
Number of subjects: 839
Study 21056439 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 839
Study 17906762 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil capsules 1 g/day
Number of subjects: 38
Study 17906762 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil capsules 2 g/day
Number of subjects: 38
Study 17906762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 38
Study 15818611 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently elevated perceived-deterrence scores
Number of subjects: 255
Study 15818611 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently low perceived-deterrence scores
Number of subjects: 255
Study 15818611 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing perceived-deterrence scores
Number of subjects: 255
Study 15818611 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing perceived-deterrence scores
Number of subjects: 255
Study 12414419 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish Interactive Threshold Algorithm (SS)
Number of subjects: 80
Study 12414419 — intervention group
Group type: COMPARATOR
Intervention: Full-threshold (FT)
Number of subjects: 80
Study 10036609 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.62 g/kg alcohol
Number of subjects: 35
Study 10036609 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral reinforcement (B)
Number of subjects: 35
Study 10036609 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 mg/kg caffeine (C)
Number of subjects: 35
Study 10036609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of behavioral reinforcement and caffeine (B + C)
Number of subjects: 35
Study 10036609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 35
Study 8526788 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis with anti‐LDL immunosorbents
Number of subjects: 30
Study 8526788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) apheresis
Number of subjects: 30
Study 31685553 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks (IXE Q4W)
Number of subjects: 657
Study 31685553 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXE Q2W)
Number of subjects: 657
Study 31685553 — intervention group
Group type: COMPARATOR
Intervention: 40 mg adalimumab every 2 weeks (ADA) followed by ixekizumab (ADA/IXE)
Number of subjects: 657
Study 31685553 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by ixekizumab (PBO/IXE)
Number of subjects: 657
Study 31685553 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks (IXE Q4W) in COAST-W
Number of subjects: 657
Study 31685553 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXE Q2W) in COAST-W
Number of subjects: 657